“Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s688. https://doi.org/10.25251/jy4cvn36.